Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
2007 Jan;70(1):147-54
While it holds significant potential, its dose-dependent effects and possible activation of NFB pathways, 166 leading to apoptosis resistance, highlight the need for careful dose optimization in clinical settings
doi: 10.1039/C9RA08284K 124 BanerjeePBagchiB
PMID: 41203627 Acta Pharmacol Sin Targeting PPAR activation sensitizes glioblastoma cells to temozolomide and reverses acquired resistance by inhibiting H3K18 lactylation
US$ 29.36
US$ 21.97
US$ 27.96
.webp)
US$ 20.32
